JSR
VC Fund
Tokyo, Japan
JSR is a VC fund in Tokyo focused on Manufacturing and Medical. JSR Corporation, together with its subsidiaries, is engaged in petrochemical products, fine chemicals, and other products businesses primarily in Japan, South Korea, China, Taiwan, Thailand, the United States, and Belgium. The company operates in three segments: elastomers, plastics, and fine chemicals, and other products. It offers elastomersproducts, such as synthetic rubbers comprising styrene-butadiene rubber, polybutadiene rubber, ethylene propylene rubber, etc.; thermoplastic elastomers and compounded products; and emulsions, including paper coating latex, styrene-butadiene latex, and acrylic emulsions. The company also offers performance chemicals, such as organic/inorganic hybrid coating materials, high-functional dispersants, industrial particles, thermal control materials, binder materials for lithium-ion batteries, etc.; other products comprising butadiene monomers, etc.; and plastics products, including ABS, AES, AS, and ASA resins. In addition, it develops and supplies semiconductor materials, which include lithography materials, such as photoresists and multilayer materials, as well as CMP materials, packaging materials, etc. Further, the company provides display materials for LCD panels, anti-reflective coatings, other functional coating materials, etc.; and optical materials, including heat-resistant transparent resin and films, UV curing optical fiber coating materials, stereo-lithography systems, etc. Additionally, it offers life sciences products, such as in-vitro diagnostics, reagents and bioprocess materials, and medical polymers, as well as lithium-ion capacitors for electricity storage. The company was formerly known as Japan Synthetic Rubber Co., Ltd. JSR Corporation was founded in 1957 and is headquartered in Tokyo, Japan.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries JSR invests in
Stages JSR invests in
Countries JSR invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Manufacturing 7 (28%)
- Medical 4 (16%)
- Health Care 4 (16%)
- Biotechnology 4 (16%)
- Semiconductor 4 (16%)
Stage
- Series D 5 (20%)
- Series B 4 (16%)
- Series C 3 (12%)
- Series A 2 (8%)
- Series E 2 (8%)
Country
- United States 12 (48%)
- Japan 2 (8%)
- India 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eric R. Johnson
CEO
|
CEO | Total investments: 4 | Find email | |
Hash Pakbaz
Chief of Digital Products and Operations
|
Chief of Digital Products and Operations | Total investments: 0 | Find email | |
Mitsunobu Koshiba
President
|
President | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
KBI Biopharma
|
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally.With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug developmentprograms. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San Diego (CA), and Leuven, Belgium. | $99.9M / Corporate Round / Oct 01, 2025 | |
Cropin
|
Founded in 2010, Cropin is a pioneer in the Agtech space, having built the first global Intelligent Agriculture Cloud. Cropin's platform enables various stakeholders in the agri-ecosystem to leverage digitization and AI at scale to make decisions that increase efficiency, scale productivity, and strengthen sustainability. Cropin has workedwith 250+ customers and has digitized 16 million acres of farmland, improving the livelihoods of more than 7 million farmers. It has built the world's largest and most diverse farming data insights over a decade, spearheading a global 'Ag-intelligence' movement with a knowledge of 488 crops, and 10000 crop varieties in 56 countries. With its AI/ML platform tailor-made for the agriculture ecosystem, Cropin has computed 0.2 billion acres of farmlands across the globe. | $13.8M / Series D / Dec 09, 2022 | |
Fluence Analytics
|
Fluence Analytics is a manufacturer of industrial and laboratory systems that produce continuous data streams. These measurements, combined with powerful, proprietary analytical tools, enable realtime optimization of process control and faster R&D for polymer and biopharmaceutical manufacturers. | $7.5M / Venture - Series Unknown / Aug 16, 2021 | |
Vedanta Biosciences
|
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $68M / Series D / Jul 21, 2021 | |
Flosfia
|
FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices. | $9.1M / Series E / Mar 26, 2021 | |
Iridia
|
Iridia is a nanotechnology company that specializes in biochemistry, molecular biology, and DNA. develop the world’s first commercially-attractive, DNA-based data storage solution. It combines DNA polymer synthesis technology, electronic nano-switches, and semiconductor fabrication technologies, Iridia is developing a highly-parallel format toenable an array of nanomodules with the potential to store data at exceptionally high density.The company was founded in 2016 and headquartered in California, United States. | $24M / Series B / Mar 16, 2021 | |
AlphaICs
|
Alphaics is advancing AI compute with its patented technology called RAP, which would revolutionize the autonomous systems. Alphaics owns several inventions critical to AI computing. Currently Alphaics is commercializing the RAP (Real AI Processing) for use in Self driving cars, Robotics, Intelligent cloud computing, UAV and more. | $8M / Series B / Jan 20, 2021 | |
Cambridge Quantum Computing
|
CQCL develops tools for the commercialisation of quantum computers by understanding quantum protocols and also quantum algorithms. In the coming period as quantum devices become more prevalent, the focus of CQCL's activity is the development of algorithms and source code. | $45M / Venture - Series Unknown / Dec 08, 2020 | |
Inpria
|
Inpria Corporation is a pioneer in extending semiconductor lithography with inorganic photoresists and other thin-films for nanoscale patterning. Inpria’s patented photo-condensed molecular oxides offer customers the unique ability to deposit – directly from solution – atomically smooth, intrinsically dense, and directly photopatternable metaloxide films, enabling advanced performance with simplified processing. | $31M / Series C / Feb 21, 2020 | |
MaRI
|
MaRI develops SAS technologies to solve daily sleep-blocking factors in a human-friendly way. They provide SAS devices to resolve hypopnea and apnea with low-frequency irradiation technology without burdening patients. Their non-contact SAS device also treats illnesses such as heart failure, arrhythmias, stroke, and diabetes. | Seed / Sep 30, 2019 | |
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does JSR invest in?
JSR invests primarily in Manufacturing, Medical and Health Care startups, most often at Series D and Series B stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact JSR?
Public channels for JSR include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at JSR?
The team at JSR includes Eric R. Johnson (CEO), Hash Pakbaz (Chief of Digital Products and Operations) and Mitsunobu Koshiba (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
